<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03498014</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2017-02/JCB-01</org_study_id>
    <nct_id>NCT03498014</nct_id>
  </id_info>
  <brief_title>Comparison of Standard Opioid Prescription Versus Prescription Guided by Pharmacogenetic Analysis in Patients With Non-cancerous Chronic Pain.</brief_title>
  <acronym>AlgoPGx</acronym>
  <official_title>Comparison of Standard Opioid Prescription Versus Prescription Guided by Pharmacogenetic Analysis in Patients With Non-cancerous Chronic Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that opioid prescription guided by patient pharmacogenetic
      profile will diminish opioid-associated undesirable effects by 50% and improve medication
      compliance.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare presence/absence undesirable events associated to opioid between groups from predefined list</measure>
    <time_frame>Month 1</time_frame>
    <description>Presence/absence of at least one undesirable event of at least grade 3 according to list in Annex 17.5 of the protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare presence/absence undesirable events associated to opioid between groups from predefined list</measure>
    <time_frame>Month 2</time_frame>
    <description>Presence/absence of at least one undesirable event of at least grade 3 according to list in Annex 17.5 of the protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare presence/absence undesirable events associated to opioid between groups from predefined list</measure>
    <time_frame>Month 3</time_frame>
    <description>Presence/absence of at least one undesirable event of at least grade 3 according to list in Annex 17.5 of the protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare presence/absence undesirable events associated to opioid between groups</measure>
    <time_frame>Month 1</time_frame>
    <description>Presence/absence of at least one undesirable event of at least grade 3 according to Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare presence/absence undesirable events associated to opioid between groups</measure>
    <time_frame>Month 2</time_frame>
    <description>Presence/absence of at least one undesirable event of at least grade 3 according to Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare presence/absence undesirable events associated to opioid between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>Presence/absence of at least one undesirable event of at least grade 3 according to Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of undesirable events associated to opioid between groups</measure>
    <time_frame>Month 1</time_frame>
    <description>Total number of undesirable event of at least grade 3 according to list in protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of undesirable events associated to opioid between groups</measure>
    <time_frame>Month 2</time_frame>
    <description>Total number of undesirable event of at least grade 3 according to list in protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of undesirable events associated to opioid between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>Total number of undesirable event of at least grade 3 according to list in protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of undesirable events associated to opioid between groups</measure>
    <time_frame>Month 1</time_frame>
    <description>Total number of undesirable event of at least grade 3 according to Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of undesirable events associated to opioid between groups</measure>
    <time_frame>Month 2</time_frame>
    <description>Total number of undesirable event of at least grade 3 according to Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of undesirable events associated to opioid between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>Total number of undesirable event of at least grade 3 according to Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare clinical therapeutic efficacy between groups</measure>
    <time_frame>Month 1</time_frame>
    <description>Patient Global Impression of Change (PGIC) score; value between 1-7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare clinical therapeutic efficacy between groups</measure>
    <time_frame>Month 2</time_frame>
    <description>Patient Global Impression of Change (PGIC) score; value between 1-7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare clinical therapeutic efficacy between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>Patient Global Impression of Change (PGIC) score; value between 1-7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare patient-reported pain between groups</measure>
    <time_frame>Day 0</time_frame>
    <description>Visual analog scare 1-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare patient-reported pain between groups</measure>
    <time_frame>Week 2</time_frame>
    <description>Visual analog scare 1-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare patient-reported pain between groups</measure>
    <time_frame>Month 1</time_frame>
    <description>Visual analog scare 1-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare patient-reported pain between groups</measure>
    <time_frame>Month 2</time_frame>
    <description>Visual analog scare 1-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare patient-reported pain between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>Visual analog scare 1-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare neuropathic pain between groups</measure>
    <time_frame>Day 0</time_frame>
    <description>DN4 score (Douleur Neuropathique 4 Questions); score between 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare neuropathic pain between groups</measure>
    <time_frame>Month 1</time_frame>
    <description>DN4 score (Douleur Neuropathique 4 Questions); score between 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare neuropathic pain between groups</measure>
    <time_frame>Month 2</time_frame>
    <description>DN4 score (Douleur Neuropathique 4 Questions); score between 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare neuropathic pain between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>DN4 score (Douleur Neuropathique 4 Questions); score between 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare benefit/risk ratio of treatment between groups</measure>
    <time_frame>Month 1</time_frame>
    <description>Overall Benefit of Analgesics Score (OBAS); score between 0-32</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare benefit/risk ratio of treatment between groups</measure>
    <time_frame>Month 2</time_frame>
    <description>Overall Benefit of Analgesics Score (OBAS); score between 0-32</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare benefit/risk ratio of treatment between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>Overall Benefit of Analgesics Score (OBAS); score between 0-32</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare quality of life between patients in each group</measure>
    <time_frame>Day 0</time_frame>
    <description>Quality of life Short Form 12 (SF-12) questionnaire; score between 0-100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare quality of life between patients in each group</measure>
    <time_frame>Month 3</time_frame>
    <description>Quality of life Short Form 12 (SF-12) questionnaire; score between 0-100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare medication compliance between groups</measure>
    <time_frame>Month 1</time_frame>
    <description>Serum concentration of tramadol, codeine or oxycodone and their metabolites by Liquid chromatography-tandem mass spectrometry (LC-MS-MS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare medication compliance between groups</measure>
    <time_frame>Month 2</time_frame>
    <description>Serum concentration of tramadol, codeine or oxycodone and their metabolites by Liquid chromatography-tandem mass spectrometry (LC-MS-MS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare medication compliance between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>Serum concentration of tramadol, codeine or oxycodone and their metabolites by Liquid chromatography-tandem mass spectrometry (LC-MS-MS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitive comparison of medication compliance between groups</measure>
    <time_frame>Month 1</time_frame>
    <description>Presence/absence of opioids or metabolites in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitive comparison of medication compliance between groups</measure>
    <time_frame>Month 2</time_frame>
    <description>Presence/absence of opioids or metabolites in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitive comparison of medication compliance between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>Presence/absence of opioids or metabolites in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of tramadol, codeine or oxycodone and their metabolites by Liquid chromatography-tandem mass spectrometry (LC-MS-MS)</measure>
    <time_frame>Day 0</time_frame>
    <description>Opioids Risk Tool (ORT): scores of 0-3 (low risk), 4-7 (moderate risk), or ≥ 8 (high risk)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare observed medication misuse between groups</measure>
    <time_frame>Month 1</time_frame>
    <description>Prescription Opioid Misuse Index (POMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare observed medication misuse between groups</measure>
    <time_frame>Month 2</time_frame>
    <description>Prescription Opioid Misuse Index (POMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare observed medication misuse between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>Prescription Opioid Misuse Index (POMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between predicted phenotype and observed metabolic ratios</measure>
    <time_frame>Month 1</time_frame>
    <description>Products/substrate ratio measured by high performance liquid chromatography-high resolution mass spectrometry (HPLC-HRMS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between predicted phenotype and observed metabolic ratios</measure>
    <time_frame>Month 2</time_frame>
    <description>Products/substrate ratio measured by high performance liquid chromatography-high resolution mass spectrometry (HPLC-HRMS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between predicted phenotype and observed metabolic ratios</measure>
    <time_frame>Month 3</time_frame>
    <description>Products/substrate ratio measured by high performance liquid chromatography-high resolution mass spectrometry (HPLC-HRMS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic profile of patients</measure>
    <time_frame>Month 1</time_frame>
    <description>Extensive Metaboliser, Intermediate Metaboliser, Poor Metaboliser or Ultra-rapid Metaboliser according to CYP2D6 phenotype and polymorphism of the glucuronyl transferase gene UGT2B7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic profile of patients</measure>
    <time_frame>Month 2</time_frame>
    <description>Extensive Metaboliser, Intermediate Metaboliser, Poor Metaboliser or Ultra-rapid Metaboliser according to CYP2D6 phenotype and polymorphism of the glucuronyl transferase gene UGT2B7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic profile of patients</measure>
    <time_frame>Month 3</time_frame>
    <description>Extensive Metaboliser, Intermediate Metaboliser, Poor Metaboliser or Ultra-rapid Metaboliser according to CYP2D6 phenotype and polymorphism of the glucuronyl transferase gene UGT2B7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between saliva and plasma concentration of opioids</measure>
    <time_frame>Month 1</time_frame>
    <description>Concentration of tramadol, codeine or oxycodone and their metabolites by Liquid chromatography-tandem mass spectrometry (LC-MS-MS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between saliva and plasma concentration of opioids</measure>
    <time_frame>Month 2</time_frame>
    <description>Concentration of tramadol, codeine or oxycodone and their metabolites by Liquid chromatography-tandem mass spectrometry (LC-MS-MS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between saliva and plasma concentration of opioids</measure>
    <time_frame>Month 3</time_frame>
    <description>Concentration of tramadol, codeine or oxycodone and their metabolites by Liquid chromatography-tandem mass spectrometry (LC-MS-MS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Non-cancerous Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Prescription as standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pharmacogenetic-guided prescription</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacogenetic analysis allowing personalized opioid prescription</intervention_name>
    <description>Genotypic of patient to determine optimal opioid treatment (tramadol, codeine or oxycodone)</description>
    <arm_group_label>Pharmacogenetic-guided prescription</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard opioid prescription</intervention_name>
    <description>Opioid prescription made without reference to patient genetic profile (tramadol, codeine or oxycodone)</description>
    <arm_group_label>Prescription as standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must have given their free and informed consent and signed the consent
             form

          -  The patient must be a member or beneficiary of a health insurance plan

          -  The patient is at least 18 years old

          -  The patient will be available for all visits

          -  Patients suffer from non-cancerous chronic pain according to HAS criteria

          -  Patient not having taking opioids in previous 2 months

          -  Patient indicated for prescription of opioids (oxycodone, codeine or tramadol) or
             patient not responding to first line treatment

        Exclusion Criteria:

          -  The subject is participating in an category I interventional study, or is in a period
             of exclusion determined by a previous study

          -  The subject refuses to sign the consent

          -  It is impossible to give the subject informed information

          -  The patient is under safeguard of justice or state guardianship

          -  The patient is pregnant or breastfeeding

          -  The patient is likely to procreate and does not use an effective method of
             contraception (contraceptive ring, surgical contraception, implant, patch,
             contraceptive pill, male and female condoms, IUD)

          -  There is a contra-indication for opioid use

          -  Patient with an addiction risk (score ≥ 8 on ORT scale).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Christophe Boyer</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Christophe Boyer, MD</last_name>
    <phone>06 83 18 85 13</phone>
    <email>jean.christophe.boyer@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Christophe Boyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Bredeau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Viel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie Maignaut-Licata, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Bregier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre Evrard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Serge Lumbroso, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marie Kinowski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2018</study_first_submitted>
  <study_first_submitted_qc>April 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2018</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

